Anzeige
Mehr »
Login
Freitag, 10.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
162 Leser
Artikel bewerten:
(1)

Med-X, Inc.: Med-X Partners with Anasac Ambiental for Nature-Cide Product Distribution in South America

Finanznachrichten News

Exclusive Distributor to Drive International Growth in Chile, Argentina, Peru and Colombia

LOS ANGELES, CA / ACCESSWIRE / January 9, 2025 / Med-X, Inc., a leading innovator of all-natural green scene solutions addressing the pest control, health and wellness markets, today announced an international distribution agreement with Anasac Ambiental S.A., providing exclusive Nature-Cide distribution rights in Chile, Argentina, Peru and Colombia.

Anasac, a Chilean company, has provided sustainable and innovative solutions that promote development and wellbeing in areas including crop protection, seeds, veterinary care, home & garden, environmental health, pets, hygiene & disinfection, and medication for over 75 years. Anasac has a presence in 19 counties worldwide with over 1,500 products. The company's subsidiary, Anasac Ambiental, produces and markets solutions for pets, gardens and green areas, as well as urban and agro-industrial pest control.

Per the terms of the agreement, Anasac Ambiental will serve as the exclusive distributor of the Nature-Cide portfolio of indoor and outdoor pest control solutions to a wide variety of professional pest management customers in Chile, Argentina, Peru and Colombia.

Matthew Mills, Chief Executive Officer of Med-X, commented: "This new international distribution agreement marks our entrance into the South American market with Anasac, a well-known Chilean leader in agriculture and pest control. Anasac Ambiental will help to introduce our flagship Nature-Cide product portfolio into Chile and neighboring countries Argentina, Peru and Colombia.

"As a major agricultural region with significant pest pressure, the need for Nature-Cide in home, agricultural and commercial applications has never been stronger. We look forward to working closely with the Anasac team to provide the Nature-Cide product portfolio as a best-in-class option to pest control operators seeking sustainable natural and effective solutions in these exciting new international markets," concluded Mills.

Francisco Di Silvestre, General Manager of Anasac Ambiental, added: "We chose to partner with Med-X due to Nature-Cide's wide range of environmentally friendly and effective solutions, providing critical solutions to the major issues that pest control operators face every day. We believe our base of customers will benefit from these cost-effective high-quality, all-natural products, and improve their pest management programs. At Anasac, we are committed to a sustainable future for pest control and look forward to the opportunity to bring Nature-Cide products to a wide variety of our customers."

About Med-X, Inc.

Med-X, Inc. is a leading innovator of biological pest control solutions addressing both consumer and professional markets globally. Nature-Cide - the Company's flagship product line - is a safer, all-natural alternative to conventional chemical products, formulated to kill or repel a wide variety of pests. Med-X's comprehensive go-to-market strategy includes leveraging strategic partnerships alongside an integrated e-commerce, brick and mortar and on-site services presence in key markets. For more information, please visit our website at www.medx-rx.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sale of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued in accordance with Rule 135 of the Securities Act. This press release may contain forward-looking statements regarding projected business performance, operating results, financial condition, and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the Company incurring operating losses and experiencing unexpected material adverse events.

Investor Relations Contact

Lucas Zimmerman
Managing Director
MZ Group - MZ North America
+1 (262) 357-2918
MXRX@mzgroup.us
www.mzgroup.us

SOURCE: Med-X, Inc.



View the original press release on accesswire.com

© 2025 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.